Search results
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new...
Morningstar· 5 days agoIpsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. “An excellent first-quarter performance ...
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
BioPharma Dive via Yahoo Finance· 7 days agoDive Brief: French pharmaceutical company Ipsen will work with privately held biotechnology company...
Ipsen, Skyhawk enter RNA targeting research collab in rare neurological diseases
Seeking Alpha· 7 days agoIpsen and Skyhawk Therapeutics collaborate to develop novel small molecules for rare neurological diseases, with potential for up to $1.8 billion in...
Ipsen Q1 Total-sales Up 13.3% At CER; Confirms 2024 Financial Guidance
RTT News· 5 days agoIpsen (IPSEY) posted sales of 822.4 million euros for the first quarter of 2024, up 13.3% at CER, or 10.9% as reported, driven by the 16.2% increase in sales of the growth ...
Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D
FierceBiotech· 7 days agoIpsen has swooped on a $1.8 billion R&D opportunity, joining with Skyhawk Therapeutics for the chance to option two candidates that could benefit from its “neuroscience expertise ...
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological...
Rome Sentinel· 7 days agoSkyhawk Therapeutics, Inc. (PRNewsfoto/Skyhawk Therapeutics)
Skyhawk’s latest biopharma collaboration is worth up to $1.8B - Boston Business Journal
The Business Journals· 6 days agoSkyhawk Therapeutics has yet another feather in its cap in the form of a new partnership deal with...
Gilead Sciences Inc (GILD) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...
GuruFocus.com via Yahoo Finance· 3 days agoThe focus remains on integrating and maximizing the current portfolio, including seladelpar. Q: Can you provide insights into the competitive dynamics expected at the launch of seladelpar, especially ...